Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test

Inclusion Criteria: * mild to moderate chronic stable plaque type psoriasis * plaques thickness of at least 200 µm * lesion(s) on the trunk or extremities (excluding palms/soles) * skin must be without disease findings Exclusion Criteria: * other skin disease * psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, psoriasis arthropathica and pustular psoriasis * treatment with any locally acting medications (including anti-psoriatics like vitamin D analogues, dithranol) within 2 weeks preceding and during the trial * treatment with any systemic medications (including anti-psoriatics like corticosteroids, cytostatics or retinoids) or medications which are known to provoke or aggravate psoriasis (e.g. beta-blocker, anti-malarial drugs, lithium) or phototherapy/PUVA within 4 weeks preceding and during the trial * treatment with any biologics within 3 months preceding and during the trial * known allergic reactions, irritations or sensitivity to the active ingredients or other components of the investigational products (e.g. Carbomere 940, propylene glycol) * drug or alcohol abuse * symptoms of a clinically significant illness within 4 preceding and during the trial * participation another clinical trial within 4 weeks of this clinical trial